Epigenetic Mechanisms in Brain Physiology and Disorders

Dr. Szyf received his Ph.D. from the Hebrew University and did his postdoctoral fellowship in Genetics at Harvard Medical School, joined the McGill University in 1989 and currently holds a James McGill Professorship and GlaxoSmithKline-CIHR Chair in Pharmacology. He is the founding co-director of the Sackler Institute for Epigenetics and Psychobiology at McGill and is a Fellow of the Canadian Institute for Advanced Research Experience-based Brain and Biological Development program. Dr. Szyf has been the founder of the first “Pharma to develop epigenetic pharmacology “Methylgene Inc. and the first journal in epigenetics “Epigenetics. Szyf lab has proposed two decades ago that DNA methylation is a prime therapeutic target in cancer and other diseases and has postulated and provided the first set of evidence that the “social environment early in life can alter DNA methylation launching the emerging field of “social epigenetics.

Zsofia Nemoda is an assistant professor at Semmelweis University in Budapest Hungary. She is a member of the Hungarian Biochemical Association, the International Society of Psychiatric Genetics, and the Hungarian Society of Human Genetics. She has 41 articles published in international journals with a cumulative impact factor of 168 and independent citations of 1139. In 2023 & 2024 she was affiliated the Douglas Mental Health University Institute, Montreal, Canada working with Dr. Linda Booij.